Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer

Protein profiles in human ovarian cancer cell lines correspond to their metabolic activity and to metabolic profiles of respective tumor xenografts

(2012) Christian Fabian et al.   FEBS Journal

Metabolic approaches to overcoming chemoresistance in ovarian cancer

(2011) Dong Hoon Suh et al.   Annals of the New York Academy of Sciences

Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning

(2011) Lara Milane et al.   Cancer Cell International

Relationship Among Glycolytic Phenotype, Grade, and Histological Subtype in Ovarian Carcinoma

(2011) Dimitrios Karantanis et al.   CLINICAL NUCLEAR MEDICINE

Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme

(2011) Amparo Wolf et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Major clinical research advances in gynecologic cancer in 2010

(2011) Dong Hoon Suh et al.   Journal of Gynecologic Oncology

Body mass index and survival in patients with epithelial ovarian cancer

(2011) Dong Hoon Suh et al.   JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH

Respiratory competent mitochondria in human ovarian and peritoneal cancer

(2011) Hwee Ying Lim et al.   MITOCHONDRION

FDG-PET/CT for diagnosis of primary ovarian cancer

(2011) Kazuhiro Kitajima et al.   NUCLEAR MEDICINE COMMUNICATIONS

Therapeutic Efficacy and Safety of Paclitaxel/Lonidamine Loaded EGFR-Targeted Nanoparticles for the Treatment of Multi-Drug Resistant Cancer

(2011) Lara Milane et al.   PLoS One

Nucleocytoplasmic shuttling of hexokinase II in a cancer cell

(2010) Catherine L. Neary et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Hexokinase II detachment from the mitochondria potentiates cisplatin induced cytotoxicity through a caspase-2 dependent mechanism

(2010) Nataly Shulga et al.   CELL CYCLE

Sugar-free approaches to cancer cell killing

(2010) N El Mjiyad et al.   ONCOGENE

Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism☆

(2009) Divya Pathania et al.   ADVANCED DRUG DELIVERY REVIEWS

Tissue Microarray : A rapidly evolving diagnostic and research tool

(2009) NazarM.T. Jawhar   ANNALS OF SAUDI MEDICINE

Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group

(2009) David S. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of the Role of Hexokinase Type II in Cellular Proliferation and Apoptosis Using Human Hepatocellular Carcinoma Cell Lines

(2009) K. J. Ahn et al.   JOURNAL OF NUCLEAR MEDICINE

The Role of 18F-FDG PET in Assessing Therapy Response in Cancer of the Cervix and Ovaries

(2009) J. K. Schwarz et al.   JOURNAL OF NUCLEAR MEDICINE

18F-FDG-PET of musculoskeletal tumors: a correlation with the expression of glucose transporter 1 and hexokinase II

(2008) Kenichiro Hamada et al.   ANNALS OF NUCLEAR MEDICINE

Expression of glucose transporters and hexokinase II in cholangiocellular carcinoma compared using [18F]-2-fluro-2-deoxy-d-glucose positron emission tomography

(2008) Bishnuhari Paudyal et al.   CANCER SCIENCE

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum

(2008) Kathleen M. Schmeler et al.   GYNECOLOGIC ONCOLOGY

Regulation of hexokinase binding to VDAC

(2008) John G. Pastorino et al.   JOURNAL OF BIOENERGETICS AND BIOMEMBRANES

Hexokinase-2 bound to mitochondria: Cancer's stygian link to the “Warburg effect” and a pivotal target for effective therapy

(2008) Saroj P. Mathupala et al.   SEMINARS IN CANCER BIOLOGY